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Abstract
Background: Markov models are a key tool for calculating expected time spent in a state, such as active life
expectancy and disabled life expectancy. In reality, individuals often enter and exit states recurrently, but standard
analytical approaches are not able to describe this dynamic. We develop an analytical matrix approach to calculating
the expected number and length of episodes spent in a state.
Methods: The approach we propose is based on Markov chains with rewards. It allows us to identify the number of
entries into a state and to calculate the average length of episodes as total time in a state divided by the number of
entries. For sampling variance estimation, we employ the block bootstrap. Two case studies that are based on
published literature illustrate how our methods can provide new insights into disability dynamics.
Results: The first application uses a classic textbook example on prednisone treatment and liver functioning among
liver cirrhosis patients. We replicate well-known results of no association between treatment and survival or recovery.
Our analysis of the episodes of normal liver functioning delivers the new insight that the treatment reduced the
likelihood of relapse and extended episodes of normal liver functioning. The second application assesses frailty and
disability among elderly people. We replicate the prior finding that frail individuals have longer life expectancy in
disability. As a novel finding, we document that frail individuals experience three times as many episodes of disability
that were on average twice as long as the episodes of nonfrail individuals.
Conclusions: We provide a simple analytical approach for calculating the number and length of episodes in Markov
chain models. The results allow a description of the transition dynamics that goes beyond the results that can be
obtained using standard tools for Markov chains. Empirical applications using published data illustrate how the new
method is helpful in unraveling the dynamics of the modeled process.
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Background
Markov chains are routinely applied to model transitions
between states. They are popular in part because they
are easy to apply [1]. Given a set of probabilities or rates
that describe the transitions between states, many useful
quantities can be calculated with Markov chains, such as
the expected time spent in a state [2–4]. In epidemiologi-
cal and health research, Markov chains and other Markov
models are, for example, often used to analyze active life
expectancy and disability-free life expectancy [5–8], or life
expectancy spent with or without specific conditions [9–
12]. These health expectancies based on Markov mod-
els are in turn used as summary measures for assessing
population health and the medical effectiveness and cost
effectiveness of interventions [1, 13, 14].
While the time spent in a specific state derived from
a Markov chain has many applications, this indicator
may hide the dynamics of the underlying process. The
expected time spent in a state gives us no information
about how often a state is entered or left, e.g., whether it
is entered only once for one long episode, or whether it is
entered and left multiple times for many short episodes.
While it can be safely assumed that some transitions occur
only once—i.e., that the expected time in the state equals
the length of the episode—in other cases a large number
of repeated transitions to and from a state are possible.
For example, this has been shown to be the case for frailty
and disability [15, 16]. Up to now,mostly simulationmeth-
ods were used for assessing this dynamic aspect ofMarkov
processes [17], and analytical solutions have been limited
to specific cases [18].
Using a discrete-time, homogeneousMarkov chain with
finite state space, we show how a general method for
Markov chains with rewards presented by van Daalen
and Caswell [19] and recently discussed in this journal by
Caswell and Zarulli [20] can be used for the calculation
of the expected number and length of episodes spent in a
state.Modifying their method suffices to arrive at an easily
applicable approach. We offer two empirical case studies
to demonstrate the insights that can be gained by using
our approach. Our first case study is a textbook exam-
ple discussed by Andersen et al. that has been analyzed
in numerous papers [21]. It is based on data from a clini-
cal trial that assessed the survival and liver functioning of
liver cirrhosis patients after treatment with prednisone, a
steroid hormone. The second case study is based on recent
work by Hardy and colleagues [15] and analyzes how
the number and length of episodes of disability among
older individuals vary depending on their levels of physical
frailty.
To assess the statistical uncertainty of our calculations,
we propose the block bootstrap as a method for esti-
mation of the sampling variance when using longitudi-
nal data. Estimating the sampling variance to conduct
statistical inference and to, for instance, calculate confi-
dence intervals has received relatively little attention in
the literature. We use simulations to assess how reliable
inference based on the block bootstrap is, and we compare
it with other methods found in the literature.
We contribute to the literature in several ways. First,
we extend the Markov chain toolbox by discussing a sim-
ple method to assess the dynamics captured by Markov
chains. Second, extensive simulations included in the sup-
plementary materials show that when using longitudinal
data the block bootstrap is preferable compared to stan-
dard model-based bootstrap approaches. Third, we re-
analyze datasets taken from the literature from a new
perspective focusing on the number of episodes in good
and bad health and the average length of these episodes.
While we keep analyses simple, they highlight how our
method could be used to shed new light on the dynamics
of liver cirrhosis and prednisone treatment and disabil-
ity and frailty. Fourth, the R code for the case studies and
simulations is available online and readily implements the
approach.
Methods
Preliminaries and basic notation
AMarkov chain describes the transitions between a given
set of states using transition probabilities. The set of
possible states is called state space. For instance, in a clas-
sic illness-death model, the state space consists of three
states: “healthy,” “ill,” (i.e., having a specific condition),
and “dead.” A Markov chain evolves in discrete time and
moves step by step from state to state; the step size can
be chosen arbitrarily, and depending on the application,
it could be 1 day, or 1 month, or 1 year. For instance, in
an illness-death model with a step size of 1 month, at the
beginning of the process, the state could be “healthy”; after
1 month, the state does not change and stays “healthy”;
after another month, it changes to “ill”; and so on, until the
state “dead” is reached, which is the so-called absorbing
state which cannot be left. States which are not absorbing
are called “transient.”
To formalize these ideas, our notation follows standard
textbook treatments of Markov chains [2–4]. Let Zt ∈ S
denote the state a discrete-time Markov chain is in at
t = 0, 1, 2, . . . , for some finite state space S consisting of
m states. The transitions between states are governed by
transition probabilities Pr
(
Zt+1 = sj|Zt = si
) = pij with
si, sj ∈ S , which capture the probability of moving from
state si at time t to state sj at time t + 1. Transition proba-
bilities only depend on the current state the Markov chain
is in at time t, and not on any previous states at t−1, t−2,
. . . . TheMarkov chain thus has theMarkov property and is
memoryless [2]. Throughout, we assume that the Markov
chain is homogeneous, i.e., that it does not vary with t.
Moreover, we assume that the Markov chain is absorbing,
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meaning that there are q > 0 states that will definitely
be reached and that will not be left. In the example of the
illness-death model, the state “dead” is absorbing.
Expected time in a state
Markov chains are usually analyzed in matrix notation.
Transition probabilities are collected in the transition
matrix P = [pij
]
, which is of dimension m × m, that is,
the entry in the ith row and jth column of P is equal to
Pr
(
Zt+1 = sj|Zt = si
)
. Arranging transition probabilities
in this way has been called a row-to-column orienta-
tion. Using the transition matrix, several quantities can
be calculated [2–4]. The time spent in any non-absorbing
(transient) state sj starting from any transient state si, nij,
can be calculated as
N = [nij
] = (In − U)−1 , (1)
where U is a transition matrix that does not include
absorbing states and thus only transition probabilities for
moving between transient states; In is an identity matrix
of dimension n×n, where n = m−q is the number of tran-
sient states; and the superscript −1 indicates the inverse
matrix. The derivation can be found, for instance, in [2].
The row sums ofN give the life expectancy conditional on
starting in state si. In the illness-death model from above,
there are two transient states: healthy and ill. This means
that the matrix N has two rows and two columns, and
the row sums equal the life expectancy starting from the
healthy state and the ill state, respectively.
Markov chains with rewards
To estimate the expected number and length of episodes,
we use Markov chains with rewards [22, 23]. An excellent
introduction to Markov chains with rewards with applica-
tion to population health was given by Caswell and Zarulli
[20]. Generally, Markov chains with rewards are based on
assigning rewards to transitions between states, and then
allow for the calculation of the expected value of rewards.
Rewards are collected in a matrix R = [rij
]
, where rij cap-
tures the reward for moving from state si to state sj. The
expected number of rewards can be calculated as [19, 24]
e = NZ (P ◦ R) 1m. (2)
1m is a column vector of length m with every entry equal
to 1; Z equals (In|0n,m−n
)
, with 0n,m−n being a matrix of
dimension n × (m − n) with all entries being equal to
0; and ◦ is used to denote the Hadamard product (i.e.,
the element-wise product). e is a vector of length n with
the ith entry, ei, giving the expected number of rewards
starting from transient state si. Note that van Daalen and
Caswell use a column-to-row orientation of the matrices,
and not a row-to-column orientation like we do here. That
means that Eq. (2) is a transposed version of the equations
provided by van Daalen and Caswell [19, 24].
The intuition behind this is as follows. N captures the
expected time spent in a state, which in the Markov chain
is equivalent to the number of visits to a state. Given that
we know how often a certain state sj is visited, P includes
the transition probabilities starting from this state, i.e.,
how probable it is that some other state sk will be visited.
If this state is visited, the reward is equal to rjk captured by
R. This means that Eq. (2) somewhat simplified amounts
to checking for each state how often it will be visited; then
checking how likely visits are to the other states; and what
the reward is if such a transition happens. Z and 1m are
used to calculate the overall sum of rewards.
Expected number and length of episodes
Given Eq. (2), it turns out to be rather easy to calculate the
number and length of episodes. Specifically, to calculate




1 si = s∗, sj = s∗
0 otherwise . (3)
Moving from some state si to s∗ thus adds 1 to the value
of rewards, i.e., the number of episodes. Other transitions,
such as staying in state s∗ or moving from s∗ to some
other state, do not add to the value of rewards. Given R,
the expected number of episodes can be calculated using
Eq. (2). The average length of episodes spent in s∗ = sj
and starting from state si, aij conditional on experiencing
at least one episode can then be calculated using
aij = nij/ei. (4)
See the supplementary materials for a proof. As an exam-
ple, consider again the illness-death model introduced
above. If the entry of R corresponding to the transition
from healthy to ill is set to one, then e will give the num-
ber of episodes in the ill state; more specifically, e will
have two entries: one entry for the expected number of
episodes of illness starting from the healthy state, and one
entry for the expected number of episodes starting from
the ill state. Combining this with entries from N like, for
instance, the expected time in illness starting from the
healthy state, allows to calculate aij.
It is also possible to calculate the number of episodes in
a subset of S , i.e., the number of episodes in several states.
This might be of interest if, for example, the state space
includes several unhealthy states, and sickness episodes
are being calculated. If S∗ denotes this subset, the entries
of R are set to
rij =
{
1 si ∈ S∗, sj ∈ S∗
0 otherwise . (5)
Note that the interpretation of the results obtained
using one of above variants in combination with Eq. (2)
depends to some degree on the structure of the Markov
chain. If, for instance, s∗ is a state that can only be left
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through an absorbing state—i.e., there can be at most one
episode of that state—then the entries of e will give the
probability of entering s∗ starting from si. Otherwise, the
approach essentially counts all transitions to state s∗ or
subset of states S∗. Replacing R in Eq. (2) with its trans-
pose RT will give the expected number of transitions out
of state s∗, which can be used to calculate the number of
recoveries.
Sampling variance estimation
Estimating the sampling variance of e as given by Eq. (2) is
not straightforward. The underlying issue is that while the
sampling variance of transition probabilities can easily be
calculated [25], this is not the case for highly non-linear
functions of the transition matrix [26].
Both simulation-based methods and the bootstrap have
been proposed as solutions for variance estimation for
Markov chains. We adopt bootstrap approaches. A com-
monly used model-based bootstrap proceeds as follows
[27]. Let ci denote the observed number of individuals in
state si, and cij denotes the observed number of transitions
from state si to sj. The maximum likelihood estimator of
pij is cij/ci. Bootstrap samples are constructed assuming
a multinomial distribution with distribution pi1, . . . , pim
and taking samples of size ci. For each bootstrap sample,
the transition matrix is calculated and, based on this, the
statistic of interest, such as e. The variance of e across
samples is used as an estimator of its sampling variance.
This approach has the major shortcoming that it
assumes that the data-generating process is (row-wise)
i.i.d., i.e., that the data follows the Markov property. In
applications with longitudinal data, the i.i.d. assumption
is potentially invalid, as repeated transitions of the same
individual are likely to be correlated.
Because of this shortcoming, we propose using a sim-
ple resampling procedure for longitudinal data based on
the block bootstrap, as discussed by Cameron and Travedi
[28] and Caswell [29], and sometimes applied in the con-
text of multistate models [30]. All data belonging to the
same individual is treated as one “block.” This could be,
for instance, a sequence of health states: at t = 0, the indi-
vidual is healthy; at t = 1, she is still healthy; at t = 2, she
has become sick, etc. Let the number of blocks be denoted
by B, and the set of all blocks is B = {b1, . . . , bB}, with bk
being the block of data belonging to individual k. For each
bootstrap replication, a new sample B∗ is formed by sam-
pling with replacement B blocks from B. As in the case of
the model-based bootstrap, the quantity of interest is cal-
culated for each sample, and its variance across sample is
used as an estimate of the sampling variance.
In the supplementary materials, we provide results of
extensive simulations showing that the block bootstrap
gives reliable variance estimates and that it performs con-
siderably better than model-based bootstrap approaches.
More specifically, the relative bias of the variance esti-
mates of the block bootstrap is much smaller than the
relative bias of model-based approaches, at least for most
simulation variants. Because of this, we apply the block
bootstrap in our first case study; for the second case
study, we do not provide variance estimates due to data
limitations.
Results
Case study 1: Prednisone treatment of liver cirrhosis
Background Worldwide, liver cirrhosis is a leading cause
of disability and death [31, 32]. Once established, liver cir-
rhosis cannot be cured and is accompanied by severe com-
plications and a greatly increased risk of mortality [33].
Medication is prescribed to prevent or alleviate complica-
tions and to reduce mortality rates among patients with
liver cirrhosis. Prednisone, a steroid hormone that was
discovered in the 1950s, has been used in the treatment of
cirrhosis complications. The results of early studies of this
therapeutic approach were promising [34].
Study population The first case study is based on a
dataset used in a classic, textbook example discussed by
Andersen et al. [21], which has been made available in
the mstate package for R [35, 36]. The dataset consists
of information on liver cirrhosis patients who entered
a clinical trial in Copenhagen from 1962 to 1969. The
main aim of the trial was to determine whether pred-
nisone would increase the survival rates of these cirrhosis
patients. The treatment group consisted of 251 individu-
als who received prednisone, and a control group of 237
patients who received a placebo. The survival rates and the
prothrombin indexes were recorded for all of the patients.
The prothrombin index is an indicator of the functioning
of the liver, expressed as a percentage, with 100% indicat-
ing normal functioning. The patients were followed until
1974.
Model The model of the first case study, shown in Fig
1, is a reversible illness-death model, i.e., an illness-death
model with recovery. The two states “normal” and “low,”
which form the state space together with the absorbing
state “dead,” are based on the prothrombin index and rep-
resent liver functioning. Prothrombin index values of less
than 70% are classified as low functioning, while index val-
ues of 70% or higher are classified as normal functioning
[35].
Methods We calculated day-to-day transition probabil-
ities in two steps. First, occurrence-exposure transition
rates were estimated for both the treatment and the con-
trol groups, i.e., the number of transitions divided by
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Fig. 1 State space of the reversible illness-death model for the liver cirrhosis example: low prothrombin index value, normal prothrombin index
value, dead
exposure measured in days. Transition rates were col-
lected in a matrix B, which was transformed into tran-
sition probabilities P through (Im − 1/2B) (Im + 1/2B)−1
[37]. Using these transition probabilities, the expected
number of episodes of normal functioning and the
expected length of episodes of normal functioning were
calculated using the approach presented in this paper.
In addition, the following quantities were estimated: the
expected time with low functioning, the expected time
with normal functioning, and the (partial) life expectancy.
All of the calculations covered a 10-year period and were,
for simplicity, based on the assumption that daily tran-
sition probabilities do not change over time or with age.
Low functioning was the starting state. This means, for
instance, that life expectancy for the control group shows
the (partial) life expectancy for the next 10 years, given
that liver functioning was abnormal. To calculate confi-
dence intervals, the block bootstrap was used. Resampling
proceeded at the level of patients, i.e., either all or none
of the exposures and transitions of an individual was
included in a bootstrap sample. 95% confidence intervals
were based on the corresponding percentiles of the boot-
strap distribution of the parameters resulting from 1000
bootstrap samples.
Results The results are shown in Table 1. In line with
well-known findings from the literature, we can see that
the remaining life expectancy of the control and the treat-
ment groups did not differ and that prednisone did not
seem to prolong survival [21, 35]. But prednisone is shown
to have affected how the patients’ remaining lifetime was
spent: members of the treatment group spent an average
of 3.7 years, or 62% of their remaining life expectancy, with
normal liver functioning, compared to only 3.1 years, or
52% of remaining life expectancy, for the control group.
Interestingly, taking prednisone was not found to increase
the number of transitions from low to normal functioning:
on average, members of the treatment group recovered
from phases of low functioning as often as members of
the placebo group. The increased lifetime with normal
liver functioning found for the treatment group seems to
have been solely due to longer episodes of normal func-
tioning, conditional on having experienced such episodes.
This result implies that prednisone neither prolonged sur-
vival nor increased the chances of recovery, but prevented
relapse and helpedmaintain normal liver functioning after
recovery, at least as measured through the surrogate out-
come of the prothrombin index.
Case study 2: Physical frailty and disability in activities of
daily living
Background In the context of population aging, disabili-
ties in activities of daily living (ADL) have been identified
as a growing public health concern and have been inten-
sively studied [38, 39]. Recovery from disability is not
uncommon. Thus, individuals often experience multiple
episodes of disability [40]. Based on the strong evidence
that physical frailty is a major driver of disability [41], we
Table 1 Results on partial durations in states for case study 1 on
liver cirrhosis and prednisone treatment
Control Treatment
Remaining life expectancy (years) 5.9 5.9
95% confidence interval [5.6, 6.3][5.5, 6.3]
Expected time low functioning (years) 2.8 2.2
95% confidence interval [2.6, 3.0][2.0, 2.5]
Expected time normal functioning (years) 3.1 3.7
95% confidence interval [2.8, 3.4][3.4, 4.0]
Expected number of episodes (normal functioning) 0.8 0.8
95% confidence interval [0.7, 0.9][0.7, 0.9]
Expected length of episodes (normal functioning, years)3.9 4.5
95% confidence interval [3.6, 4.2][4.3, 4.8]
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can expect that frail individuals will experience more and
longer episodes of disability than nonfrail individuals.
Study population Our second case study uses the results
of an analysis by Hardy et al. of data collected in New
Haven, CT, USA, from 1998 to 2004 [15]. The dataset cap-
tures the disability status of 754 study participants aged 70
and older, with a median follow-up period of 60 months.
The participants’ disability levels were assessed during
monthly telephone interviews, in which they were asked
about their levels of independent functioning in four
activities of daily living: bathing, dressing, walking, and
transferring. The participants’ physical frailty levels were
measured based on whether their rapid gait test score was
higher than 10 s. Each individual’s disability status was
assessed at baseline and then every 18 months.
Model Hardy et al. distinguished between four states,
shown in Fig. 2: “no disability,” “mild disability,” “severe
disability,” and the absorbing state “dead” [15]. The par-
ticipants were classified as having mild disability if they
were disabled in one or two ADLs, and they were clas-
sified as having severe disability if they were disabled
in three or four ADLs. Hardy et al. published counts of
transition events and exposures, which allow for the cal-
culation of monthly transition rates between the states.
The transition rates were transformed into monthly tran-
sition probabilities, as described for the first case study.
These transition probabilities were used to calculate the
expected time spent in each state, the expected num-
ber of episodes of disability, and the expected episode
length. For the number of episodes, we counted the tran-
sitions to disability, i.e., we counted both the transitions
to mild or severe disability from the no disability state.
All of these measures were calculated over a period of
60 months (i.e., the median follow-up period) and differ-
entiated between frail and nonfrail states. For this case
study, the block bootstrap cannot be applied, as it requires
patient-level data and information on individual trajecto-
ries, while we only have access to the aggregated transition
rates. Because of this, we refrain from resampling and do
not report confidence intervals or standard errors.
Results Table 2 shows the results for the expected time
in each of the states, the expected number of disability
episodes, and the average length of disability episodes.
All of these results are conditional on starting in the no
disability state at the beginning of the 60-month period
under consideration. This means, for instance, that a non-
frail and non-disabled older individual over a period of
60 months can expect to spend roughly 53 months, or
89% of the period under consideration, in the no disabil-
ity state. For a frail individual, on the other hand, only
36 months, or 60% of the period under consideration,
were lived without disability. When we added together
the time spent in mild and severe disability, we found
that frail individuals spent a considerably longer average
period time in disability (13.6 months) than nonfrail indi-
viduals (2.2 months). This difference was partly driven by
the expected number of disability episodes experienced
during the 60-month period. On average, frail individu-
als experienced three times as many episodes of disability
as nonfrail individuals. In addition, the disability episodes
Fig. 2 State space of the model of Hardy et al. [15]
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Table 2 Results on partial durations in states for case study 2
based on transition rates taken from [15]
Nonfrail Frail
Expected time non-disabled (months) 53.4 36.2
Expected time mild disability (months) 1.8 9.5
Expected time severe disability (months) 0.4 4.0
Expected number of disability episodes 0.7 2.2
Expected length of disability episodes 3.1 6.2
were twice as long for frail than for nonfrail older individ-
uals.
Discussion
The two empirical case studies presented here high-
light the usefulness of assessing the expected number
and length of episodes. The first case study found that
prednisone treatment neither prolonged survival nor
increased the probability of recovery, but that it reduced
the likelihood of relapse and extended episodes of nor-
mal liver functioning, thus showing its efficacy compared
to a placebo treatment. The second case study showed
that there were considerable differences in both the num-
ber and the length of disability episodes between frail
and nonfrail elderly individuals. Both examples show that
the new perspective presented in this paper is helpful in
unraveling the dynamics of the modeled process and that
it allows for a detailed assessment of differences between
groups. The results of our approach could also be used
to enrich analyses of cost effectiveness of a given treat-
ment like prednisone by, for instance, assessing the costs
of increasing the number of episodes in good health.
While our analyses show the usefulness of the method
discussed in this paper, they servemostly as examples, and
their validity might be somewhat limited by, for instance,
not controlling for important stratifying variables. The
second example might also suffer from its reliance on
monthly transition data, which could be too coarse to give
reliable estimates of the number of episodes [42]. While
the use of such data might also affect estimates of the
expected time spent in a state [43], there is evidence that
for many applications, the estimation of the time spent
in a state is relatively insensitive to the time unit used
[44]. Thus, calculating the number and length of episodes
might require additional care.
More generally, for the approach presented in this paper
to yield valid results, valid estimates of transition probabil-
ities are required, and theMarkov chainmust be an appro-
priate representation of the process that is being modeled.
The assumptions about, for example, theMarkov property
or the homogeneity of the Markov chain, must accurately
reflect this process. While many potential issues associ-
ated with Markov process modeling have been tackled in
the literature, and can often be addressed when estimat-
ing transition rates or probabilities, our method does not
account for these issues specifically [11, 45–47]. Our sim-
ulation results presented in the supplementary materials
show that in case of correlated longitudinal data variance
estimates can be improved by using a block bootstrap.
Not taking into account the correlation structure can
lead to substantially overestimating the sampling variance,
although its data demands are higher than for simpler
bootstrap methods. Irrespective of the bootstrap vari-
ant, resampling yields rather unreliable results for small
samples, though.
Our approach can be applied to arbitrary complex
state spaces. This feature could, for instance, be use-
ful when transition probabilities are age-dependent (or
time-dependent). In such a case, the state space could be
expanded to include age: e.g., “aged 50 and non-disabled,”
“aged 51 and non-disabled,” and so on. In this case, the
values in the matrix of rewards R that relate to transitions
from “non-disabled” to “disabled” are set to 1, e.g., for the
transition from “aged 50 and non-disabled” to “aged 51
and disabled”. Furthermore, our method can be applied
not only to cases in which the number and length of
episodes are themselves of interest, but also to the assess-
ment of the fit of the model: in cases in which a Markov
approach is used and a priori knowledge about the process
and the number of episodes is available, the results can be
compared to the predictions of the model.
Conclusions
In this paper, we built on previous work by van Daalen and
Caswell and presented a method based on Markov chains
with rewards that can be used to calculate the expected
number and length of episodes in a state for a discrete-
time, finite-state Markov chain [19]. Variance estimation
can proceed using the block bootstrap. To illustrate how
easily this approach can be applied, we presented two case
studies: an illness-death model of liver functioning with-
out recovery, and a more complex model of disability. In
both cases, our approach yielded insights into the mod-
eled process that went beyond the results that could be
obtained using standard tools for Markov chains.
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Supplementary information accompanies this paper at
https://doi.org/10.1186/s12963-020-00217-0.
Additional file 1: This file contains a proof of Eq. (4), a description of the
simulations we conducted to assess the performance of the bootstrap
approaches, and the results of the simulations.
Additional file 2: We provide twelve files of R code which allow to
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brief description of the individual files of code.
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